Benzalkonium bromide as a new potential instillation drug for bladder cancer: Hypothesis and pilot study

Medical Science Monitor

Volumn 17, Issue 12, 2011, Pages

  Xu, Ran ^a   Zhang, Lei ^a   Zhao, Xiaokun ^a   Jiang, Hongyi ^a   Lu, Qiong ^a   Zhong, Zhaohui ^a   Hou, Yi ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Benzalkonium bromide; Bladder cancer; Intravesical therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BENZALKONIUM BROMIDE; CREATININE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; BLADDER MUCOSA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTOSCOPY; HEMATURIA; MALE; NONHUMAN; PAIN; PILOT STUDY; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 82755165778     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882110     Document Type: Article

References (18)

1. Sievert KD, Amend B, Nagele U et al: Economic aspects of bladder cancer: what are the benefits and costs? World J Urol, 2009; 27(3): 295-300
2. Gurtowska N, Kloskowski T, Drewa T: Ciprofloxacin criteria in antimicrobial prophylaxis and bladder cancer recurrence. Med Sci Monit, 2010; 16(10): RA218-23
3. Sylvester RJ, van der Meijden AP, Oosterlinck W et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006; 49(3): 466-77
4. Wirth M, Plattner VE, Gabor F: Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv, 2009; 6(7): 727-44
5. Babjuk M, Oosterlinck W, Sylvester R et al: EAU Guildelines on nonmuscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol, 2011; 59(6): 997-1008
6. Kakizoe T: Development and progression of urothelial carcinoma. Cancer Sci, 2006; 97(9): 821-28
7. Braakhuis BJ, Tabor MP, Kummer JA et al: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res, 2003; 63(8): 1727-30
8. De Saint Jean M, Brignole F, Bringuier AF et al: Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci, 1999; 40(3): 619-30
9. Riechelmann H, Deutschle T, Stuhlmiller A et al: Nasal toxicity of benzalkonium chloride. Am J Rhinol, 2004; 18(5): 291-99
10. Debbasch C, Brignole F, Pisella PJ et al: Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci, 2001; 42(3): 642-52
11. Hamard P, Blondin C, Debbasch C et al: In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol, 2003; 241(12): 1037-43
12. Enomoto R, Suzuki C, Ohno M et al: Cationic surfactants induce apoptosis in normal and cancer cells. Ann NY Acad Sci, 2007; 1095: 1-6
13. Solsona E, Iborra I, Ricós JV et al: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol, 1999; 161(4): 1120-23
14. th edn. WB Saunders, Philadelphia Section XV, Chapter 75
15. Duggan B, Williamson K: Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need posters?). Curr Opin Urol, 2004; 14(5): 277-86
16. McBain AJ, Ledder RG, Moore LE et al: Effects of quaternary-ammonium-based formulations on bacterial community dynamics and antimicrobial susceptibility. Appl Environ Microbiol, 2004; 70(6): 3449-56
17. Patarca R, Fletcher MA: Effects of benzalkonium salts on eukaryotic and microbial G-protein-mediated processes and surface membranes. Crit Rev Oncog, 1995; 6(3-6): 327-56
18. Patarca R, Rosenzwei JA, Zuniga AA et al: Benzalkonium salts: effects on G protein-mediated processes and surface membranes. Crit Rev Oncog, 2000; 11(3-4): 255-305